Incidence and Severity of imAEs

General Considerations

Incidence and Severity of imAEs

Combination therapy with 2 ICIs is associated with both earlier imAE onset and higher levels of immune-mediated toxicity than either one alone.1

Because less-common toxicities may be life threatening and initial presentation may be mild, with nonspecific symptoms, prompt diagnosis and treatment are required.1

References:

  1. Daniels GA, Guerrera AD, Katz D, Viets-Upchurch J. Challenge of immune-mediated adverse reactions in the emergency department. Emerg Med J. 2019 Jun;36(6):369-377.
  2. Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628.

Connect with us on social

MSD Egypt, 67 – El Tesseen St., Address Building, Fifth Settlement, New Cairo.
In case you need any updates or you have an inquiry or need to report on an adverse reaction, you can contact:

+20226145100

dpoc_egypt@merck.com

Veeva Code: EG-KEY-00280

Expiration Date: 10/07/2024